Amarantus Strengthens Management Team! Nice!
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has appointed Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Mr. Segal will be responsible for in-licensing and out-licensing activities, as well as merger and acquisition opportunities across therapeutics and diagnostics areas. Ms. Clark will be responsible for overseeing all regulatory activities, including support of business development activities.
"I am pleased to welcome Mr. Segal and Ms. Clark to Amarantus at this key time in our pipeline's life-cycle as we begin to evaluate business development opportunities for our current asset base, as well as review various product opportunities that have been presented to the Company," said Gerald E. Commissiong, President & CEO of Amarantus. "Successful transactions in the biopharmaceutical industry are achieved with proper preparation from a product development and regulatory standpoint, continued relationship building and experience in understanding the best strategic fit for both parties involved in discussions. We believe today's additions will build tremendous value to the Company as we continue on our path to build a world-class biotechnology company addressing the many unmet medical needs of patients around the world."
Mr. Segal is a 30-year veteran of the biopharmaceutical industry, including successful experiences while at Johnson & Johnson, Cephalon, Valeant, two start-ups and most recently Impax Pharmaceuticals. Mr. Segal's career encompasses 22 years of front-line transactional experience during which time he identified and closed transactions valued in excess of $2.6B and generated non-dilutive capital through partnerships in excess of $270M. Mr. Segal's forte is selectively identifying, pursuing, structuring and closing strategically prudent transactions that build shareholder value.
Ms. Clark brings over 20 years' experience to Amarantus, with over ten years of professional multidisciplinary biotech and pharmaceutical experience, primarily in regulatory, research and development. Ms. Clark recently served as Regulatory Affairs Specialist, Project Management & Regulatory Operations at Pharmacyclics. Previously, she served as Drug Safety Coordinator and Senior Archivist at Johnson & Johnson Pharmaceutical Research & Development. At Pharmacyclics, she was a team member that brought IBRUTINIB from discovery into Phase 3 clinical development and was an integral member of the business development team that executed $975M BTK transaction with Janssen Biotech, Inc. (IBRUTINIB). Ms. Clark was also an integral member of the business development team that completed transactions with Novo Nordisk for the Factor VIIa inhibitor, PCI-27483, and the pan-HDAC deal with Les Laboratories Servier (ABEXINOSTAT). Ms Clark has prepared, submitted and maintained 7 IND's, 1 NDA, several Orphan Drug Applications, FDA meeting packages and Fast Track designations.
About Amarantus
